MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CytRx Company Profile (NASDAQ:CYTR)

Consensus Ratings for CytRx (NASDAQ:CYTR) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.50 (258.65% upside)

Analysts' Ratings History for CytRx (NASDAQ:CYTR)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016FBR & Co.Reiterated RatingBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016AegisBoost Price TargetBuy$9.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015OppenheimerReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for CytRx (NASDAQ:CYTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/11/2016Q116($0.26)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.24)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.27)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2015Q115($0.21)$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.27)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.25)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.20)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q413($0.18)$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.17)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.22)($0.33)$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.19)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q113($0.15)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2013Q4 2012($0.20)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312$0.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CytRx (NASDAQ:CYTR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.21)($0.21)($0.21)
Q2 20163($0.22)($0.19)($0.20)
Q3 20163($0.22)($0.17)($0.20)
Q4 20163($0.36)($0.17)($0.24)
(Data provided by Zacks Investment Research)
Dividend History for CytRx (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CytRx (NASDAQ:CYTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CytRx (NASDAQ:CYTR)
DateHeadline
06/23/16 08:14 AMExplore small cell lung cancer pipeline market report 2016 - WhaTech
06/23/16 08:14 AMExxon Mobil Corporation (NYSE:XOM) increased 0.45%: CytRx Corporation (NASDAQ:CYTR), The Dow Chemical ... - KC Register
06/16/16 07:53 AMMedovex: Even Cheaper Now - Seeking Alpha
06/08/16 08:18 PMAnalysts Offer Insights on Healthcare Companies: Amag Pharmaceuticals (NASDAQ: AMAG), Cytrx (NASDAQ: CYTR ... - Analyst Ratings
06/07/16 10:57 AMStocks Active on Selling Boundary- CytRx (NASDAQ:CYTR), Synopsys (NASDAQ:SNPS), Vonage Holdings (NYSE:VG) - Seneca Globe
06/07/16 05:02 AMCYTRX CORP Files SEC form 8-K, Other Events -
06/06/16 08:08 AMCytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting - [at noodls] - LOS ANGELES, June 6, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of three posters ...
05/31/16 08:12 AMCytRx to Present at Jefferies 2016 Global Healthcare Conference - [at noodls] - LOS ANGELES, May 31, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Olivia Ware, Chief Commercial ...
05/27/16 11:28 AMCYTRX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities -
05/21/16 12:59 AMAnalysts Offer Insights on Healthcare Companies: Cytrx (NASDAQ: CYTR) and Acceleron Pharma (NASDAQ: XLRN) - Markets.co - Analysts Offer Insights on Healthcare Companies: Cytrx (NASDAQ: CYTR) and Acceleron Pharma (NASDAQ: XLRN)Markets.coFBR Capital analyst Christopher James reiterated a Buy rating on Cytrx Corp. (NASDAQ: CYTR) today. The company's shares closed yesterday at $2.37. According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -17.4% and a ...
05/19/16 12:04 PMCYTRX CORP Financials -
05/12/16 06:37 AMMast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City -
05/11/16 09:03 PMCytRx Co. (CYTR) Issues Quarterly Earnings Results - Washington News Wire - Washington News WireCytRx Co. (CYTR) Issues Quarterly Earnings ResultsWashington News WireCytRx logo CytRx Co. (NASDAQ:CYTR) announced its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07, MarketBeat reports.CytRx Co. (CYTR) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPSWeb Breaking Newsall 15 news articles »
05/11/16 08:07 AMCytRx reports 1Q loss -
05/11/16 08:00 AMCytRx Reports First Quarter 2016 Financial Results - [PR Newswire] - LOS ANGELES, May 11, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three ...
05/10/16 04:29 PMCYTRX CORP Files SEC form 10-Q, Quarterly Report -
05/05/16 09:29 PMBiotech Stocks Worth a Closer Look: CytRx Corporation (NASDAQ:CYTR), Array BioPharma Inc. (NASDAQ:ARRY) - Street Register - Biotech Stocks Worth a Closer Look: CytRx Corporation (NASDAQ:CYTR), Array BioPharma Inc. (NASDAQ:ARRY)Street RegisterCytRx Corporation (NASDAQ:CYTR) lost -5.45% by the end of recent close at $3.12. For the ongoing quarter, the 4 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of $-$0.26/share, which would compare with ...and more »
04/28/16 10:35 PMCytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference - PR Newswire (press release) - CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor ConferencePR Newswire (press release)LOS ANGELES, April 28, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen, Vice President of Business Development and ...and more »
04/28/16 08:26 AMCytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference - [at noodls] - LOS ANGELES, April 28, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen, Vice President ...
04/26/16 07:53 PMStrong Performing Stocks, Apr-26 – UBNT, KEN, CYTR, BCEI, TPUB, AVXL, MSFT, CRC - CytRx Corporation (CYTR) traded at $3.57 + 0.2299 (6.88 percent ... and -84.27 percent during the past four quarters. Tribune Publishing Co (TPUB) traded at $11.75 + 4.23 (56.25 percent). The company is +48.76 percent in the last four weeks, +27.44 ...
04/26/16 12:20 AMStock Update (NASDAQ:CYTR): CytRx Corporation and PRA Health Sciences Receive Gold Awards for Excellence in ... - Smarter Analyst - Stock Update (NASDAQ:CYTR): CytRx Corporation and PRA Health Sciences Receive Gold Awards for Excellence in ...Smarter AnalystCytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, ...and more »
04/25/16 08:30 AMCytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year - [at noodls] - LOS ANGELES, April 25, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical ...
04/20/16 09:48 PMHealthcare Movers to Target: Cara Therapeutics, Inc. (NASDAQ:CARA) , CytRx Corporation (NASDAQ:CYTR) - WsNews 4investors - Healthcare Movers to Target: Cara Therapeutics, Inc. (NASDAQ:CARA) , CytRx Corporation (NASDAQ:CYTR)WsNews 4investorsCytRx Corporation (NASDAQ:CYTR) started out trading at $3.35 and hit to day high price of $3.35 while it touched the day low price of $3.15. Shares have gone down -4.78% to close at $3.19. The company shares changing hands with the volume of 881.14 ...and more »
04/20/16 08:21 AMCytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 - [at noodls] - LOS ANGELES, April 20, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three aldoxorubicin clinical ...
04/19/16 10:34 PMAnalysts Offer Insights on Healthcare Companies: Cytrx (NASDAQ: CYTR), Regeneron Pharmaceuticals (NASDAQ ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Cytrx (NASDAQ: CYTR), Regeneron Pharmaceuticals (NASDAQ ...Markets.coCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytrx (NASDAQ: CYTR), Regeneron Pharmaceuticals (NASDAQ: REGN), Five Prime Therapeutics Inc (NASDAQ: FPRX) and Alnylam Pharmaceuticals ...
04/13/16 10:27 AMGlobal Osteosarcoma Therapeutics Pipeline Review, H1 2016 - Research and Markets - Inc. CytRx Corporation Eleison Pharmaceuticals LLC EntreChem, S.L. Exelixis, Inc. Gradalis Inc. Ipsen S.A. Isofol Medical AB Karyopharm Therapeutics, Inc. Kolltan Pharmaceuticals, Inc. MediaPharma s.r.l. Merck & Co., Inc. Merrimack Pharmaceuticals ...
04/05/16 04:24 PMETF’s with exposure to CytRx Corp. : April 5, 2016 -
04/04/16 11:38 AMAnalysts Release New Consensus Estimates for CYTRX CORP. (NASDAQ:CYTR) - Hints News Network - Analysts Release New Consensus Estimates for CYTRX CORP. (NASDAQ:CYTR)Hints News NetworkCYTRX CORP. (NASDAQ:CYTR) received a 'Strong Buy' rating on average from equities analysts who cover the company. The rating was compiled from from the 5 investment firms that maintain analyst coverage on the company. 1 analyst currently rates the ...
04/04/16 11:38 AMCompany Update (NASDAQ:CYTR): CytRx Corporation Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin ... - Smarter Analyst - Company Update (NASDAQ:CYTR): CytRx Corporation Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin ...Smarter AnalystCytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached the target number of progression events in its pivotal, global phase 3 clinical trial with aldoxorubicin ...and more »
04/04/16 08:07 AMCytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis - [at noodls] - LOS ANGELES, April 4, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached the target ...
04/02/16 08:26 PM5 Analysts Rate CYTRX CORP. (NASDAQ:CYTR) an Average of Strong Buy - Hints News Network - 5 Analysts Rate CYTRX CORP. (NASDAQ:CYTR) an Average of Strong BuyHints News NetworkAnalysts have issued a 'Strong Buy' rating for CYTRX CORP. (NASDAQ:CYTR), according to data recently reviewed by Zacks. The company was rated a “Strong Buy” on average from the 5 analysts who currently cover the stock. 1 of the equities analyst ...Analyst update:Cytrx Corp. was rated by Jefferies & Co to InitiateThe Duncan Independent (press release) (blog)all 4 news articles »
03/31/16 08:43 PMHow did Jefferies & Co rate Cytrx Corp.? - The Duncan Independent (press release) (blog) - How did Jefferies & Co rate Cytrx Corp.?The Duncan Independent (press release) (blog)Deviations of actual gains from prediction amounts have a stong impact on a firm's share price. As of this moment, analysts anticipate Cytrx Corp. stock to attain $7.3 in approaching year. By surveying as many as 5 analysts in research, this amount is ...
03/27/16 12:02 PMGene Test Helped Docs Plan Breast Ca Therapy - Test use was significantly associated with younger age, white race, academic centers, private insurance, and pT2/pN0(i+) grade 2 to 3 disease, Peter Kabos, MD, of the University of Denver, Aurora, CO, and colleagues ... Pharma (Inst), CytRx (Inst), Eisai ...
03/23/16 02:12 PMETF’s with exposure to CytRx Corp. : March 23, 2016 -
03/23/16 12:51 PMJefferies & Co affirms CYTRX CORP. (NASDAQ:CYTR) rating of Initiate - Hints News Network - Jefferies & Co affirms CYTRX CORP. (NASDAQ:CYTR) rating of InitiateHints News NetworkCYTRX CORP. (NASDAQ:CYTR) opened at $2.56 on Friday. The company's 50-day moving average is $2.38 and it's two-hundred-day moving average is $2.59. The firm has a mkt cap of $181.49M and a price-to-earnings ratio of . CYTRX CORP. has a ...and more »
03/22/16 08:33 AMCytRx to Present New Data Using Its Proprietary LADR™ Technology at the 2016 American Association for Cancer Research Annual Meeting - [at noodls] - LOS ANGELES, March 22, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will present two posters ...
03/21/16 12:29 PMCytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/14/16 09:11 PMCytrx Corp. (NASDAQ:CYTR) rated an average of Strong Buy by 5 of analysts - Engelwood Daily - Cytrx Corp. (NASDAQ:CYTR) rated an average of Strong Buy by 5 of analystsEngelwood DailyEquities analysts gave Cytrx Corp. (NASDAQ:CYTR) a 'Strong Buy' rating, we've learned from data compiled by Zacks. The Strong Buy rating was computed from the average rating of the equities analysts who cover the company. To create this rating, the 5 ...and more »
03/11/16 08:16 AMCytRx reports 4Q loss -
03/11/16 08:00 AMCytRx Reports 2015 Financial Results - [PR Newswire] - LOS ANGELES, March 11, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ...
03/11/16 05:02 AMCYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition -
03/11/16 05:02 AMCYTRX CORP Files SEC form 10-K, Annual Report -
02/29/16 08:00 AMCytRx to Present at the Cowen & Company's 36th Annual Health Care Conference - [PR Newswire] - LOS ANGELES, Feb. 29, 2016 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at Cowen and Company's 36th Annual Health Care Conference on Wednesday, March 9th at 10:40 a.m. Eastern Time. The conference will take place at the Boston Marriott Copley Place. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
02/20/16 10:14 AMKahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities Litigation - PR Newswire (press release) - Kahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities LitigationPR Newswire (press release)... Claims Administrator: CytRx Corp. Securities Litigation, c/o Gilardi & Co. LLC, P.O. Box 40007, College Station, TX 77842, (877) 368-7060. Copies of the Notice and Claim Form can also be downloaded from the website, www.CytrxSecuritiesLitigation.com.and more »
02/19/16 05:31 PMKahn Swick & Foti, LLC Announces Proposed Settlement of CytRx Corporation Securities Litigation - Further information may also be obtained by directing your inquiry in writing to the Claims Administrator, Gilardi & Co, LLC. at the address listed above, or by visiting the website, www.CytrxSecuritiesLitigation.com. Visit PR Newswire for Journalists ...
02/18/16 10:18 AMCytRx Corporation CCO Olivia Ware and CEL-SCI CEO Geert Kersten on a new potential breakthrough cancer therapy - Dazu rss.dw.de weiter: Mitsubishi issues apology to US POWs used as wartime slave labor weiterlesen ... Weitere Nachricht von rss.dw.de: Rupert Murdoch hands CEO job at Fox to son James but stays as co-Chairman weiterlesen
02/17/16 05:13 PMMerriman's Reedland Capital Division Acts as Co-Financial Advisor to CytRx Corporation - Nasdaq - Merriman's Reedland Capital Division Acts as Co-Financial Advisor to CytRx CorporationNasdaqSAN FRANCISCO- February 17, 2016- Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQB:MERR), today announced that CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in ...
02/17/16 10:03 AMWill CytRx (CYTR) Continue to Surge Higher? -
02/11/16 03:36 PMCYTRX CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement -
02/09/16 04:21 PMCYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation -
About CytRx

CytRx logoCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTR
  • CUSIP:
Key Metrics:
  • Previous Close: $2.37
  • 50 Day Moving Average: $2.54
  • 200 Day Moving Average: $2.56
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $158.22M
  • Current Quarter EPS Consensus Estimate: $-0.78 EPS
Additional Links:
CytRx (NASDAQ:CYTR) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha